What is Zacks Research's Forecast for BDX FY2025 Earnings?

Becton, Dickinson and Company (NYSE:BDX - Free Report) - Stock analysts at Zacks Research reduced their FY2025 earnings per share (EPS) estimates for shares of Becton, Dickinson and Company in a report issued on Thursday, April 10th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will post earnings per share of $14.40 for the year, down from their prior forecast of $14.43. The consensus estimate for Becton, Dickinson and Company's current full-year earnings is $14.43 per share. Zacks Research also issued estimates for Becton, Dickinson and Company's Q3 2026 earnings at $4.05 EPS, Q4 2026 earnings at $4.52 EPS, FY2026 earnings at $15.55 EPS, Q2 2027 earnings at $4.14 EPS and FY2027 earnings at $16.79 EPS.

Several other analysts also recently commented on the company. Barclays cut their target price on Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating on the stock in a research note on Monday, April 7th. Piper Sandler upped their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an "overweight" rating in a research note on Tuesday, January 28th. Finally, StockNews.com upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Wednesday, April 2nd. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $275.71.

Becton, Dickinson and Company Stock Down 1.0 %

Becton, Dickinson and Company stock traded down $1.91 during trading hours on Monday, hitting $198.50. The stock had a trading volume of 4,062,543 shares, compared to its average volume of 1,710,218. The stock's 50-day moving average price is $220.84 and its 200-day moving average price is $228.58. Becton, Dickinson and Company has a 12-month low of $193.03 and a 12-month high of $251.99. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $56.99 billion, a P/E ratio of 32.97, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%.

Institutional Trading of Becton, Dickinson and Company

A number of institutional investors and hedge funds have recently bought and sold shares of BDX. Norges Bank purchased a new stake in shares of Becton, Dickinson and Company in the fourth quarter worth about $735,523,000. T. Rowe Price Investment Management Inc. grew its holdings in shares of Becton, Dickinson and Company by 36.1% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier's stock valued at $2,751,187,000 after purchasing an additional 3,219,317 shares in the last quarter. Kovitz Investment Group Partners LLC raised its stake in Becton, Dickinson and Company by 392.4% during the fourth quarter. Kovitz Investment Group Partners LLC now owns 3,416,665 shares of the medical instruments supplier's stock valued at $775,139,000 after purchasing an additional 2,722,829 shares in the last quarter. First Eagle Investment Management LLC grew its stake in shares of Becton, Dickinson and Company by 31.4% in the 4th quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier's stock worth $1,004,132,000 after buying an additional 1,057,879 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Becton, Dickinson and Company by 15.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 6,175,899 shares of the medical instruments supplier's stock valued at $1,401,126,000 after buying an additional 810,345 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP David Shan sold 500 shares of the company's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the completion of the transaction, the executive vice president now owns 5,741 shares of the company's stock, valued at approximately $1,377,840. This represents a 8.01 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jeffrey William Henderson acquired 1,500 shares of the stock in a transaction dated Monday, February 10th. The stock was acquired at an average price of $233.62 per share, for a total transaction of $350,430.00. Following the completion of the transaction, the director now directly owns 8,015 shares of the company's stock, valued at approximately $1,872,464.30. This represents a 23.02 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 4,078 shares of company stock valued at $915,986 over the last quarter. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company announced that its Board of Directors has authorized a stock buyback program on Tuesday, January 28th that authorizes the company to buyback 10,000,000 outstanding shares. This buyback authorization authorizes the medical instruments supplier to purchase shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company's board of directors believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 31st. Shareholders of record on Monday, March 10th were issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 2.10%. The ex-dividend date of this dividend was Monday, March 10th. Becton, Dickinson and Company's dividend payout ratio is presently 69.10%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.